N-(4-Amino-1-Benzyl-3-Hydroxy-5-Phenyl-Pentyl)-3-Methyl-2-(2-Oxo-Tetrahydro-Pyrimidin-1-Yl)-Butyramide,Compound With 5-Oxopyrrolidine-2-Carboxylic Acid

Process chemists evaluating this complex for large-scale cGMP manufacture of HIV-1 protease inhibitor pharmacophores report that the pyroglutamate counterion moderates the aggressive hygroscopicity of the free amine intermediate. Pre-loading the amino alcohol backbone as its 5-oxopyrrolidine-2-carboxylic acid salt stabilizes the primary amine against oxidative discoloration, a failure mode documented during storage of unprotected batch LP-2024-07 where HPLC purity at 215 nm dropped by 2.3% over 14 days under ambient atmosphere. The complex is charged directly into amide bond formation with 2,6-dimethylphenoxyacetic acid using 1.05 equivalents of the acid chloride generated in situ with thionyl chloride in tetrahydrofuran at –10 to –5 °C. After aqueous bicarbonate quench and crystallization from isopropanol/water 70/30 v/v, the resulting lopinavir free base is isolated in 93–96% yield with a diastereomeric excess exceeding 99.5% as per USP <621> chiral HPLC. Residual pyroglutamic acid partitions into the aqueous layer and is monitored below the 0.15% threshold in the final API by ion chromatography per EP 2.2.38. Terminal product meets EP 10.8 and USP 43 monographs for Lopinavir.

Solving light-sensitive degradation during preparative HPLC purification of the free amine

When a downstream R&D program requires the free amine with enantiomeric purity above 99.8%, the complex is cleaved under strictly controlled conditions. An aqueous slurry adjusted to pH 8.5–9.0 with 2 M potassium carbonate at 5 °C liberates the amine, which is immediately extracted into degassed dichloromethane containing 0.1% w/w butylated hydroxytoluene. Flash chromatography on neutral alumina (activity grade III) eluting with heptane/ethyl acetate/triethylamine 80/18/2 v/v/v removes co-extracted pyroglutamic acid. The pooled fractions are concentrated under reduced pressure at jacket temperature not exceeding 30 °C and lyophilized from acetonitrile/water to yield an off-white lyophilisate. Photoinstability is pronounced; exposure of the solution to standard laboratory fluorescent light for 4 hours generates the N-oxide degradant at 0.7–1.2 area-%. All operations from pH adjustment to final drying are therefore performed under sodium vapor lamp illumination or with ambered glassware wrapped in aluminum foil. The purified free amine is immediately consumed in peptide mimetic scaffold elaboration, most commonly SC-CO₂ mediated coupling with carbobenzyloxy-protected unnatural amino acids, or stored at –20 °C under argon for no longer than 72 hours before use.

Formulators tasked with developing a once-daily fixed-dose combination of lopinavir and a pharmacokinetic booster have evaluated the pyroglutamate complex as a directly compressible intermediate that circumvents the need for pre-granulation acidification. Blends containing 68% w/w microcrystalline cellulose (Avicel PH-102), 20% w/w of the complex, 8% w/w crospovidone, 2% w/w colloidal silicon dioxide, and 2% w/w sodium stearyl fumarate were compacted on a rotary tablet press equipped with 19 × 9.5 mm oval tooling at a compression force of 18–22 kN. Tablet hardness measured by an Erweka TBH-325 tester exceeded 120 N with friability below 0.2% after 100 drops per USP <1216>. Under dissolution testing with USP apparatus II at 75 rpm in 900 mL of pH 6.8 phosphate buffer containing 2% polysorbate 80, the pyroglutamate salt maintained a supersaturated state of 45 μg/mL for 180 minutes, whereas the free base diluted from a pre-dissolved stock precipitated within 30 minutes. The observation translates into a viable direct-compression pathway for markets where spray-dried amorphous solid dispersions of lopinavir copovidone incur prohibitive licensing complexity.

From milligram R&D batches to metric ton campaigns: maintaining polymorphic form consistency

Contract manufacturing organizations supplying intermediate for abbreviated new drug application holders mandate that the crystalline form of the complex remains invariant between the pilot batch used for process validation and subsequent commercial lots. Powder X-ray diffraction spectra must overlay within ±0.2° 2θ for all characteristic reflections at 6.8, 11.3, 14.9, 18.2, and 21.7° 2θ (Cu Kα radiation, 40 kV, 40 mA, scan rate 2°/min). A single unanticipated endotherm at 167–169 °C by differential scanning calorimetry at 10 °C/min under 50 mL/min nitrogen purge confirms the thermodynamically stable Form A, while a shoulder preceding the melt endotherm signals residual Form B contamination and triggers batch rejection under the quality agreement. To lock the polymorphic outcome, the neutralization-crystallization protocol fixes the antisolvent (water) addition rate at 1.2 mL/min into a 45 °C isopropanol solution seeded with 0.5% w/w micronized Form A crystals. Slurrying the wet cake in acetone for 2 hours at ambient temperature prior to vacuum drying at 40 °C and ≤10 mbar for 12 hours reduces residual isopropanol below 500 ppm as required by ICH Q3C Class 3 solvent limits. Shipment to the drug product manufacturer occurs in double polyethylene bags packed inside fibre drums with desiccant pouches; container closure integrity is validated per USP <1207>.

If the downstream reaction involves Pd-catalyzed hydrogenolysis, what precautions render the pyroglutamate complex compatible?

The 1-benzyl substituent on the pentyl backbone is a latent site for catalytic debenzylation, exploited when API manufacturers prepare the des-benzyl derivative for structure-activity relationship screening. Pre-coordination of palladium by the pyroglutamate nitrogen can poison the catalyst surface and reduce turnover frequency, a phenomenon observed when 5% Pd/C (Type 487, Johnson Matthey) achieves only 45% conversion after 8 hours under 1 atm H₂ in the presence of the intact complex. Removal of the counterion before hydrogenolysis is therefore mandatory. The complex is suspended in ethyl acetate, washed twice with 1 M aqueous sodium phosphate buffer pH 9.0, and the organic layer dried over magnesium sulfate. Following filtration and solvent swap to methanol, hydrogenolysis proceeds to 98% completion within 2.5 hours at 25 °C. After catalyst filtration through a 0.45 μm PTFE membrane and evaporation, the debenzylated intermediate is re-complexed with pyroglutamic acid in methyl ethyl ketone if a stable salt is required for long-term storage. The entire sequence is encased within an engineering control requiring a nitrogen-inerted vessel, because the debenzylated free amine autoxidizes with an induction period of less than 20 minutes when exposed to headspace oxygen above 5000 ppm.

Quality control departments that support first-to-file generic submissions stock the complex as a high-purity working standard for impurity method development under ICH Q3A. A batch crystallized thrice from acetone/water and dried to loss on drying below 0.10% serves as the primary marker for the amino alcohol pentyne dimer, which elutes at relative retention time 1.34 on a Zorbax SB-C8, 150 × 4.6 mm, 3.5 μm column maintained at 40 °C with a mobile phase of buffer (pH 3.2 triethylamine phosphate)–acetonitrile 65/35 v/v and UV detection at 210 nm. The standard is assigned a potency value against the WHO International Chemical Reference Standard for lopinavir using mass balance protocol per USP <11>, accounting for residual solvents by headspace GC-FID, inorganic impurities by ICP-MS per USP <233>, and water by Karl Fischer coulometric titration. Each vial of standard is flame-sealed under argon and shipped with a certificate of analysis traceable to NIST SRM 928. The format allows ANDA filers to defend impurity quantitation limits of 0.05% during FDA pre-approval inspections without circulating the proprietary synthesis pathway of the active pharmaceutical ingredient.

Pyroglutamic acid stoichiometry deviation: impacts on hot-melt extrusion torque and strand quality

Thermal processing of the complex by twin-screw extrusion for amorphous solid dispersion manufacture exposes the material to a narrow processing window. Formulations composed of the complex and polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer (Soluplus) at a 30/70 w/w ratio were compounded on a Leistritz ZSE 18 mm co-rotating twin-screw extruder with L/D 40:1, operating at screw speed 200 rpm and barrel zone temperatures increasing from 120 °C to a die temperature of 155 °C. When the pyroglutamic acid content in the complex deviated by ±3 mol% from stoichiometry—either due to incomplete salt formation or residual free acid—extruder torque fluctuated from a steady-state 7.2 N·m to 8.9–10.4 N·m, and strand breakage occurred within 12 minutes of feeding. Microscopy of quenched strands showed undissolved crystalline domains with birefringence under polarized light at molar excess of free acid, while free amine-deficient complex led to a viscosity drop evidenced by melt fracture. Monitoring the acid/amine molar ratio to within 1.00 ± 0.02 via potentiometric titration per EP 2.2.20 prior to extrusion is consequently enforced by the quality risk management file. Milled extrudate sieved through a 250 μm screen and blended with 0.5% magnesium stearate was compressed into tablets exhibiting a single glass transition at 84 °C by modulated DSC, and dissolution in FaSSIF media yielded an area under the curve 1.9-fold higher than that of the equivalent physical mixture.

Within pilot facilities operating continuous-flow hydrogenation and coupling sequences, the complex is selected as the primary input stream because it dissolves cleanly in 0.1 M methanolic ammonia at a concentration of 150 g/L without generating the gelatinous polyadducts observed with the hydrochloride salt. A Corning Advanced-Flow G1 reactor with 10 glass fluidic modules and a heat exchange zone maintained at 20 °C delivers the methanolic solution into a palladium-charcoal packed column (CatCart, 6 × 150 mm) for a residence time of 95 seconds at 5 bar backpressure. After exiting the hydrogenation module, the stream combines with a solution of 2,6-dimethylphenoxyacetyl chloride in anhydrous THF at a molar ratio of 1:1.03, flowing through a residence tube of 12 mL volume at 0.8 mL/min. In-process FTIR monitors the carboxamide carbonyl stretch at 1645 cm⁻¹ to confirm complete conversion before a continuous liquid-liquid extraction separates the product. The uninterrupted campaign produced 4.7 kg of lopinavir crude over 14 hours of runtime, with only one flow interruption attributable to a pressure spike above 9 bar, which was cleared by reversing the flow direction for 30 seconds. The absence of a free amine drying step, enabled by immediate downstream consumption of the complex, eliminates a unit operation that historically contributed inter-batch variability averaging 3.6% RSD in residual water.